BAG3 and hepatocellular carcinoma: Notably, the METTL21A inhibition has been shown to revitalize BAG3 degradation, trigger M1 macrophage reprogramming, and improve the efficacy of sorafenib, which offers the novel combined Methylation and molecular chaperone intervention approach to the treatment of hepatocellular carcinoma (67).